Home > Browse Research > Life Sciences > Biotechnology > Biologics

Biologics: market research reports

A biologic medical product or a biologic or biological, is a medicinal product such as a vaccine, blood or blood component, gene therapy, tissue, recombinant therapeutic protein, or living cells that are used as therapeutics to treat diseases. Biologics are created by biologic processes, rather than being chemically synthesized. Biologics can be composed of sugars, proteins, or nucleic acids or a complex combination of these substances.

They may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources that can be human, animal, or microorganism.

Biologics market research reports and industry analysis

Biologic Drug R&D in China - Current State and Future Development 5/1/2013 \| published by: JZMed, Inc. ... biological medicines. In the recent several years growing numbers of Chinese pharma and biopharma companies have been steadily increasing their investment in innovative drug R&D, including the discovery and development of novel biologics. The current ... \| read more...	$3,685.00
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry 4/30/2013 \| published by: GlobalData ... the Pharmaceutical Industry report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 ... \| read more...	$2,995.00
Biologicals in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developing 1460 biological drugs in 3194 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 868 drugs. Biologicals In ... \| read more...	$9,371.25
R&D Productivity – The State of Research and Development in the BioPharmaceutical Industry (CBRSV043) 4/1/2013 \| published by: CBR Pharma Insights, LLC ... from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better ... \| read more...	$3,900.00
Singapore Pharmaceutical Industry 2H12 3/20/2013 \| published by: Emerging Markets Direct Reports ... value added by the sector, human resources, cost of operation and capital expenditure, plus the profile, comparative matrix and SWOT analysis of the industry leading players: Luye Pharma Group Limited, Star Pharmaceuticals Limited, and Pharmesis ... \| read more...	$450.00
Comparison of Biopharmaceutical Industry between China and India 3/1/2013 \| published by: JZMed, Inc. ... untreatable diseases. The fast growth of the global biopharmaceutical market has prompted all global major pharma companies to increase their investment in biopharmaceuticals, which has resulted in a dramatic change in their R&D strategy and ... \| read more...	$4,285.00
Conference Documentation: Lyophilisation: Freeze-Drying in Pharmaceuticals and Biopharmaceuticals 2/25/2013 \| published by: SMI Publishing, Ltd ... to combat the issues with the industry and enhance our existing solutions. With SMi’s first event in this sector we will be bringing KOL's from the industry together to speak on the latest topics of ... \| read more...	$788.78
The Indian Pharmaceutical Industry 2013: Coming of Age in a Global Market 1/29/2013 \| published by: Espicom Healthcare Intelligence ... on 31st March 2012. Ranbaxy reported revenue of Rs.99,769 million (US$2,145 million) for the calendar year ended 31st December 2011, making it the leading company in terms of revenue. Of the companies listed, 18 reported ... \| read more...	$1,390.00
Pharmaceutical Industry in the United States 1/1/2013 \| published by: Aruvian's R'search ... and vaccines that prevent and treat over 150 conditions were approved by the FDA.3 The FDA also gave the go-ahead for numerous new indications for previously approved medicines, allowing physicians to tailor treatment strategies to ... \| read more...	$450.00
Point-of-Delivery Drug Reconstitution Systems to 2017 1/1/2013 \| published by: Greystone Research Associates ... temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination. ... \| read more...	$3,850.00
Biologic Imaging Reagents: Technologies and Global Markets 1/1/2013 \| published by: BCC Research ... of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017 Coverage of fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); ... \| read more...	$5,450.00
Biologic Therapeutic Drugs: Technologies and Global Markets 1/1/2013 \| published by: BCC Research ... annual growth rates (CAGRs) through 2017 Coverage of large market segments such as monoclonal antibodies (mAb), therapeutic proteins, and vaccines Examination of the competitive environment with a special focus on how new products and technologies ... \| read more...	$5,450.00
Single-Use Technologies for Biopharmaceuticals: Global Markets 1/1/2013 \| published by: BCC Research ... for 2012, and projections of compound annual growth rates (CAGRs) through 2017 In-depth discussion of key market segments, such as membrane adsorbers, bioreactors, mixing, tangential flow filtration, tubing, connectors, preassembled tubing and rigging, depth filtration, ... \| read more...	$5,450.00
Innovation in the Prefilled Syringe Market - Biologics and Autoinjection Devices Shaping Future R&D Trends 12/14/2012 \| published by: GBI Research ... Biologics and Autoinjection Devices Shaping Future R&D Trends”, which provides insights into possible future avenues of R&D in the prefilled syringe market. This includes an overview of problems and possible solutions, as well as discussion ... \| read more...	$3,500.00
Rheumatoid Arthritis in Brazil, Russia, and China – How Are Payers and Prescribers Promoting or Limiting Growth in the Biologics Markets 11/30/2012 \| published by: Decision Resources ... by a growing prevalent population with greater access to medical care and by rheumatologists’ increasing use of more aggressive treatments. Increased government spending on healthcare and improved penetration of biological agents make this an attractive ... \| read more...	$10,000.00
Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis 11/30/2012 \| published by: GlobalData ... 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics ... \| read more...	$3,495.00
Orencia (Rheumatoid Arthritis) Forecast and Market Analysis 11/30/2012 \| published by: GlobalData ... 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics ... \| read more...	$3,495.00
Cimzia (Rheumatoid Arthritis) Forecast and Market Analysis 11/30/2012 \| published by: GlobalData ... 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics ... \| read more...	$3,495.00
Actemra (Rheumatoid Arthritis) Forecast and Market Analysis 11/30/2012 \| published by: GlobalData ... 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics ... \| read more...	$3,495.00
Advanced Wound Care: World Market Prospects 2013-2023 11/28/2012 \| published by: Visiongain ... lifestyle related disorders such as diabetes and obesity. Visiongain predicts the total advanced wound care market to be worth $16.3bn in 2023. The move from traditional wound care treatment to advanced wound care started in ... \| read more...	$2,497.00
How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis? 11/16/2012 \| published by: Decision Resources ... include five tumor necrosis factor-alpha (TNF-a) inhibitors, Bristol-Myers Squibb’s selective costimulation modulator Orencia, Roche’s MabThera (Roche/Biogen Idec Chugai/Zenyaku Kogyo’s B-cell inhibitor Rituxan), and the more recently launched interleukin-6 (IL-6) inhibitor Actemra/RoActemra from Roche/Chugai. However, two ... \| read more...	$10,000.00
U.S. Payer and Prescriber Attitudes Toward Novel Oral, Topical, and Biologic Emerging Agents in the Psoriasis Market: Implications for Market Access 11/14/2012 \| published by: Decision Resources ... Biotech/Janssen-Cilag). Further intensifying the future competitive landscape, two agents in late-stage trials for psoriasis offer the advantage of oral formulation: Pfizer’s Jak inhibitor tofacitinib and Celgene’s phosphodiesterase-4 (PDE-4) inhibitor apremilast. Efficacious IL-17 inhibitors are also ... \| read more...	$10,000.00
How Will U.S. Payers and Prescribers Determine the Success of New Biologics and Oral Entrants and Currently Marketed Biologics in Psoriatic Arthritis and Axial Spondyloarthritis? 11/9/2012 \| published by: Decision Resources ... of 100 rheumatologists and 25 pharmacy directors at MCOs that offer both commercial health insurance and Medicare plans. PsA and SpA—which refers to a disease continuum including both undifferentiated (nonradiographic) axial SpA and ankylosing spondylitis ... \| read more...	$10,000.00
Hernia Repair Device Markets and Procedures 11/6/2012 \| published by: Kalorama Information ... are consistent from year to year. This report, Hernia Repair Device Markets and Procedures looks at the hernia repair industry segment. New product innovation, a steady demand for superior products by surgeons, and increasing procedure ... \| read more...	$3,995.00
Innovative R&D and Dealmaking Opportunities: Oncology Biologics: Novel Therapeutic Antibodies, Proteins, and Peptides 10/24/2012 \| published by: Decision Resources ... sales: Roche/Chugai’s Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan/MabThera (rituximab). Developments in the design of MAbs have progressed rapidly, moving from murine-based biologics to humanized and fully human antibodies. More recently, companies have been creating and ... \| read more...	$10,000.00

< prev 1 2 3 next >